OUR TEAM  GROUP 9
LAB 2 WRITEUP
Descriptive Statistics
Human Study
Varying Statistics for LPS
LPS Dose 
Average Inflammotin (pg/ml) 
Standard Deviation 
End Point # 
Standard Error 
Average Age

0mg 
3.834 
1.523010177 
10 
0.481618106 
66.7

5mg 
8.932 
1.593931547 
10 
0.504045412 
68.1

10mg 
61.622 
30.11069386 
10 
9.521837451 
68

15mg 
657.941 
212.9429762 
10 
67.33848166 
67.9

Overall LPS Doses

Inflammotin (pg/ml)

Average 
183.08225

Standard Deviation 
297.1368812

End Point # 
40

Standard Error 
46.98146608

Rat Study
Varying Statistics for LPS Doses
LPS Dose 
Average Inflammotin (pg/ml) 
Standard Deviation 
End Point # 
Standard Error

0mg 
10.516 
2.225551617 
5 
0.995296941

10mg 
11.112 
7.402885924 
5 
3.310671231

Overall LPS Doses

Inflammotin (pg/ml)

Average 
10.814

Standard Deviation 
5.163022801

End Point # 
10

Standard Error 
1.632691166

Results
Human Study
Rat Study
Analysis
Human Study
The data consisted of results from 4 different groups of subjects (0mg, 5mg, 10mg, and 15mg doses), so a oneway ANOVA test was run to find a pvalue. The test yielded a pvalue of 1.4 x 10^{16}, which means that the experiment had a percent uncertainty of less than 0.01%. This is much lower than the accepted 5% (or a pvalue of 0.05), which means that the results were statistically different between groups. This leads to the conclusion that different dosages of the LPS will produce significantly different levels of Inflammotin in humans.
After running the ANOVA test, a Bonferroni correction was needed to test the statistical difference in each individual comparison. There were 6 comparisons based on the 4 groups (0 vs. 5mg, 0 vs. 10mg, 0 vs. 15mg, 5 vs. 10mg, 5 vs. 15mg, and 10 vs. 15mg). This means that the original alpha value of 0.05 needed to be adjusted; dividing 0.05 by 6 resulted in a new pvalue of 0.008333. If the individual comparison yielded a pvalue less than 0.008333, then the comparison was statistically different. Each comparison was less than 0.008333 (8.59631 x 10^{07}, 9.94377 x 10^{06}, 1.39436 x 10^{08}, 3.01859 x ^{05}, 1.57101 x 10^{08}, and 6.4824 x 10^{08}, respectively), so all the results were statistically different from each other.
Rat Study
The data consisted of results from only 2 different groups (0mg and 10mg doses), so a Ttest was run to find the pvalue. The test yielded a pvalue of 0.867403497, which means that the experiment had a percent uncertainty of about 86.7%. This is much higher than the accepted 5% (or a pvalue of 0.05), which means that the results were not statistically different between groups. This leads to the conclusion that giving rats the LPS did not increase Inflammotin levels.
Summary/Discussion
Based on the data and Anova results, the level of Inflammotin in the blood in the Human Study generally increases as the dosage of LPS increases. This is because a pvalue of 1.4 x 10^{16} was achieved (pvalue < .05), meaning that the differences in dosages are significantly different. They have a clear direct, positive relationship. However, in the rat study, the dosage of LPS had no clear relationship with the amount of Inflammotin in the blood as the pvalue achieved was .867403487, meaning that the two groups are not significantly different (pvalue > .05). All in all, as the LPS dosage rises in humans, the Inflammotin levels rise; however, due to the pvalue outcome, the same cannot be said about rats with confidence.
